Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” ...

Essentially, this means the heart didn't do its job too well and over-suppress cardiac function. The results "support the hypothesis that LVOT gradient reductions can be decoupled from LVEF ...

In principle, the blood volume passing through a stenotic valve (aortic stenosis) is equal to the blood volume proximal to the stenosis or in the LVOT (Figure 4). The stroke volume is equal to ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

The Cirrus-HCM trial is an open-label, four-week study evaluating the efficacy of two dosages (50 mg and 100 mg) of EDG-7500 in patients diagnosed with either obstructive or nonobstructive HCM. The ...

Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise.

Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.